Cellectar Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Cellectar Biosciences has a total shareholder equity of $26.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $42.9M and $16.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$40.03m |
| Equity | US$26.17m |
| Total liabilities | US$16.74m |
| Total assets | US$42.91m |
Recent financial health updates
We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully
Aug 08
Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation
Aug 23Recent updates
We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully
Aug 08Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
Feb 12Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation
Aug 23Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19
Aug 05Cellectar announces reverse stock split
Jul 21We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
May 10Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
Jan 20Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?
Oct 05Cellectar shares fall after mid-stage CLR 131 trial data fails to impress
Jun 04We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely
May 20Cellectar Biosciences EPS beats by $0.03
May 10Cellectar gets notification of formal grant from Australian and Mexican patent authorities
Apr 27Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer
Jan 12Cellectar Bio readies stock offering
Dec 23We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
Nov 30
Cellectar Biosciences EPS beats by $0.05
Nov 09Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors
Nov 05Financial Position Analysis
Short Term Liabilities: CLRB's short term assets ($41.4M) exceed its short term liabilities ($16.3M).
Long Term Liabilities: CLRB's short term assets ($41.4M) exceed its long term liabilities ($474.3K).
Debt to Equity History and Analysis
Debt Level: CLRB is debt free.
Reducing Debt: CLRB had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLRB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CLRB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 22% each year